Advertisement
Screener

Caribou Biosciences, Inc. (CRBU) EBITDA

Caribou Biosciences, Inc. (CRBU) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$24.71M*; Operating income -$25.34M; Depreciation and amortization $625.00K*.
  • 2026-03-31: Basis Reported; EBITDA -$25.63M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$27.77M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA -$28.77M*; Operating income -$29.40M; Depreciation and amortization $631.00K*.

Complete source-backed ebitda history.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$24.71M*-$25.34M$625.00K*$1.50M-1648.70%*$1.00K*-$22.79M*(m)$18.94M(m)(m)
2026-03-31Reported-$25.63M(m)(m)(m)-1069.29%$72.00K-$26.98M(m)$20.61M(m)$0.00
2025-12-31Reported-$27.77M(m)(m)(m)-704.67%(m)(m)(m)(m)(m)(m)
2025-09-30Reported-$28.77M*-$29.40M$631.00K*$2.20M-1308.87%*$115.00K*-$25.18M*(m)$22.40M(m)$0.00
2025-06-30Reported-$46.41M*-$47.58M$1.17M*$2.67M-1740.19%*$418.00K*-$28.26M*(m)$27.69M(m)(m)
2025-03-31Reported-$41.75M(m)(m)(m)-1774.25%$1.04M-$36.73M(m)$35.53M(m)$0.00
2024-12-31Reported-$37.69M(m)(m)(m)-1814.68%(m)(m)(m)(m)(m)(m)
2024-09-30Reported-$37.06M*-$38.24M$1.18M*$2.02M-1831.08%*$673.00K*-$32.66M*(m)$30.42M(m)$0.00
2024-06-30Reported-$42.65M*-$43.50M$856.00K*$3.46M-1231.09%*$2.24M*-$32.87M*(m)$35.48M(m)$0.00
2024-03-31Reported-$45.29M(m)(m)(m)-1864.64%$1.45M-$37.20M(m)$33.79M(m)$0.00
2023-12-31Reported-$36.7M(m)(m)(m)-1031.53%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$13.05M*-$14.63M$1.58M*$23.66M-55.17%*$4.75M*-$28.79M*(m)$28.58M(m)$0.00
2023-06-30Reported-$32.25M*-$32.87M$617.00K*$3.75M-858.88%*$2.55M*-$15.19M*(m)$26.50M(m)$0.00
2023-03-31Reported-$30.53M(m)(m)(m)-871.70%$2.03M-$27.94M(m)$25.71M(m)$0.00
2022-12-31Reported-$30.07M(m)(m)(m)-814.52%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$26.09M*-$26.54M$450.00K*$3.30M-789.80%*$1.35M*-$22.38M*(m)$19.99M(m)$0.00
2022-06-30Reported-$28.07M*-$28.43M$358.00K*$4.19M-669.68%*$2.62M*-$21.87M*(m)$22.58M(m)$0.00
2022-03-31Reported-$20.55M(m)(m)(m)-771.21%$723.00K-$21.67M(m)$13.92M(m)$0.00
2021-12-31Reported-$20.13M(m)(m)(m)-786.71%(m)(m)(m)$15.11M(m)(m)
2021-09-30Reported-$18.36M*-$18.62M$260.00K*$3.98M-461.55%*$930.00K*-$14.97M*(m)$15.83M(m)$0.00
2021-06-30Reported-$15.73M*-$15.96M$230.00K*$1.48M-1065.99%*$484.00K*-$16.48M*(m)$12.33M(m)$0.00
2021-03-31Reported-$12.95M(m)(m)(m)-816.77%$22.00K$20.31M(m)$10.16M(m)$0.00
2020-12-31Reported-$14.99M(m)(m)(m)-1523.68%(m)(m)(m)$12.02M(m)-$354.00K
2020-09-30Reported-$8.00M*-$8.23M$226.00K*$1.20M-668.03%*$14.00K*-$8.69M*(m)$6.18M(m)-$213.00K
2020-06-30Reported(m)-$2.25M(m)$8.48M(m)(m)(m)(m)$7.58M(m)-$50.00K
2020-03-31Reported(m)-$10.43M(m)$1.70M(m)(m)(m)(m)$8.64M(m)-$1.20M

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported-$144.7M(m)(m)(m)-1296.70%$1.36M-$110.99M(m)$109.44M(m)-$550.00K
2024-12-31Reported-$162.69M(m)(m)(m)-1627.87%$4.88M-$138.20M(m)$130.15M(m)-$9.00K
2023-12-31Reported-$112.53M(m)(m)(m)-326.40%$11.61M-$93.29M(m)$112.08M(m)$193.00K
2022-12-31Reported-$104.78M(m)(m)(m)-756.46%$6.45M-$90.97M(m)$82.23M(m)$70.00K
2022-09-30Rolling(m)-$96.23M*(m)$12.72M*(m)(m)(m)(m)$71.61M*(m)(m)
2022-06-30Rolling(m)-$88.31M*(m)$13.39M*(m)(m)(m)(m)$67.45M*(m)(m)
2022-03-31Rolling(m)-$75.84M*(m)$10.68M*(m)(m)(m)(m)$57.20M*(m)(m)
2021-12-31Reported-$66M(m)(m)(m)-687.59%$2.12M-$32.52M(m)$52.26M(m)$321.00K
2021-12-31Rolling(m)-$68.16M*(m)$9.60M*(m)(m)(m)(m)$53.44M*(m)(m)
2021-09-30Rolling(m)-$62.97M*(m)$8.02M*(m)(m)(m)(m)$50.35M*(m)-$354.00K*
2021-06-30Rolling(m)-$52.58M*(m)$5.24M*(m)(m)(m)(m)$40.70M*(m)-$567.00K*
2021-03-31Rolling(m)-$38.87M*(m)$12.25M*(m)(m)(m)(m)$35.95M*(m)-$617.00K*
2020-12-31Reported-$35.22M(m)(m)(m)-284.96%$317.00K-$33.22M(m)$34.42M(m)-$1.82M
2020-12-31Rolling(m)-$36.12M*(m)$12.36M*(m)(m)(m)(m)$34.42M*(m)-$1.82M*
2019-12-31Reported-$33.55M(m)(m)(m)-579.72%$884.00K-$32.01M(m)$23.64M(m)-$7.54M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22